NEURACAP
M&A UpdateUpdated · 7 pages · Free to read

Regenerative Medicine M&A update, 14–28 September 2026

A bi-weekly briefing on Regenerative Medicine industry events, public-market movers and M&A activity for September 14–28, 2026, covering seven public names, sector-wide regulatory catalysts and the trailing precedent-transaction record, for operators, acquirers and advisors tracking sector direction.

For information only. Not an appraisal or a fairness opinion.

The deeper read: Regenerative Medicine Sector Outlook — September 2026

Key figures

Sector median move (close-to-close)
+0.9%
vs S&P 500 +0.8%
Surrozen, Inc. (SRZN) two-week move
+66.1%
Sep 14–28, 2026
Materiality bar (sector-relative)
5.3%
threshold for move significance
Sector valuation lens
10.0x
median, precedent transactions

Read the report

NeuraCap

BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE

HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › REGENERATIVE MEDICINE

Pathway Rulings Move Value While the Deal Record Holds Still

This update covers Regenerative Medicine movers, company news and transactions for September 14–28, 2026.

September 14–28, 2026

Prepared by NeuraCap AI · Confidential

Market data through 2026-09-28 · events and transactions from the two-week period 2026-09-14 → 2026-09-28

Regenerative Medicine Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice

1

1 / 7

Executive summary

Regulatory outcomes carried the two-week period ended September 28, 2026: 5 of 7 covered Regenerative Medicine names rose, with a median move of +0.9% against +0.8% for the S&P 500. Surrozen, Inc. (SRZN) led the set at +66.1% after its Investigational New Drug submission to the FDA for SZN-8141, while MiMedx Group, Inc. (MDXG) moved on a federal court ruling vacating FDA's classification determination for AXIOFILL. No new sector transactions were recorded in the window, leaving the trailing record at 23 precedent deals against a 10.0x median valuation lens.

Key findings

  • Regulatory outcomes, not deals, moved the sector this period.
  • Surrozen surged 66.1% on an FDA IND submission for SZN-8141.
  • A federal court vacated FDA's AXIOFILL classification for MiMedx.
  • No new transactions printed; the 23-deal precedent record holds at 10.0x.

What each page shows

The analyst’s walkthrough of the deck, page by page.

  1. 01
    BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE

    HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › REGENERATIVE MEDICINE

    Cover slide introducing the Regenerative Medicine bi-weekly industry events and M&A update for September 14–28, 2026.

    This bi-weekly update covers Regenerative Medicine industry events, public-market movers and transactions for September 14–28, 2026. We use it to walk through what changed, who moved and why, what transacted, and what it means for the people who act on this sector.

    Everything on this page

    BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › REGENERATIVE MEDICINE Pathway Rulings Move Value While the Deal Record Holds Still This update covers Regenerative Medicine movers, company news and transactions for September 14–28, 2026. September 14–28, 2026 Prepared by NeuraCap AI · Confidential Market data through 2026-09-28 · events and transactions from the two-week period 2026-09-14 → 2026-09-28 Regenerative Medicine Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 1

  2. 02
    THE BI-WEEKLY BOTTOM LINE

    Regulatory Outcomes, Not Transactions, Carried the Period

    Summarizes the two-week period across seven covered names, showing regulatory outcomes rather than deal activity drove results.

    Five of the seven names we cover finished higher, with a median move of +0.9% against the S&P 500's +0.8% — a period where the set modestly outperformed the broader market. Surrozen led the group after its FDA submission, while MiMedx's court ruling reopened the tissue-versus-biologic classification question that shapes the sector's regulatory map. No new transactions were recorded, so the trailing record of 23 precedent deals and its 10.0x median lens stand unchanged. So what: this period's signal is regulatory, and it is the one worth carrying into client conversations.

    Everything on this page

    THE BI-WEEKLY BOTTOM LINE Regulatory Outcomes, Not Transactions, Carried the Period The two-week period in one page · 7 covered names, close-to-close · September 14–28, 2026 Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Driver attributions use calibrated language and are NeuraCap reads of the recorded evidence. Regenerative Medicine Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 2 1 Most of the Covered Set Finished Higher 5 of 7 covered names rose; the median move was +0.9%, just ahead of the S&P 500 at +0.8%. 2 One Regulatory Submission Produced the Period's Largest Move Surrozen, Inc. (SRZN) gained +66.1% over the two-week period, including +108.4% on Sep 24. Shares moved following the company's Investigational New Drug submission to the FDA for SZN-8141 in diabetic macular edema. 3 A Court Ruling Puts Tissue Classification Back in Play MiMedx Group, Inc. (MDXG) announced a federal court vacated FDA determinations that AXIOFILL is not minimally manipulated and should be classified as a biological product. Tissue pathway versus biologic licence remains the sector's central question. 4 The Transaction Record Stood Still No new sector transactions were recorded in the window. The trailing record carries 23 precedent transactions, and NeuraCap's valuation lens for the sector sits at a median of 10.0x. +66.1% Best mover — Surrozen, Inc. (SRZN) worst: AORT -8.1% · 5 up / 2 down of 7 covered +0.9% Sector median two-week return vs S&P 500 +0.8%

  3. 03
    PUBLIC MARKET MOVERS

    A Single Regulatory Step Outran the Whole Set

    Ranks the two-week share-price moves for the seven covered names against the sector median and the S&P 500.

    Surrozen's +66.1% move, including a +108.4% single-day jump on September 24, dominates the ranking and pulls the sector median to +0.9%, just ahead of the S&P 500's +0.8%. The materiality bar for this set sits at 5.3%, so several other moves cross the line for a client conversation even without Surrozen's outlier. We link each move only to the filings and headlines recorded in the window, and where no driver is on record we say so plainly. So what: one regulatory data point can reset the whole distribution, and price alone does not tell you why.

    Everything on this page

    PUBLIC MARKET MOVERS A Single Regulatory Step Outran the Whole Set Bi-Weekly moves, close-to-close · September 14–28, 2026 · sector median +0.9% · S&P 500 +0.8% · materiality bar ±5.3% (sector-relative) Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Attribution links each move only to filings and headlines recorded in the window; where no driver is recorded, the page says so. Calibrated language throughout — NeuraCap reads, not asserted causation. Regenerative Medicine Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 3 Bi-Weekly return per company · teal above zero, amber below · sector median +0.9% Surrozen, Inc. (SRZN) +66.1% Shares moved following Surrozen, Inc. (SRZN) submitting an Investigational New Drug application to the FDA for SZN-8141 in diabetic macular edema, reported Sep 24, the same day the stock moved +108.4%. Pre-commercial regenerative names still reprice on regulatory steps rather than on revenue. COMPANY-SPECIFIC Organogenesis Holdings Inc. (ORGO) -8.0% No notable in-window news was identified that clearly explains the move. Organogenesis Holdings Inc. (ORGO) returned -8.0% against a median move of +0.9% across the covered set. Skin substitute sellers are read on reimbursement durability more than on any two-week move. UNEXPLAINED Artivion, Inc. (AORT) -8.1% No notable in-window news was identified that clearly explains the move. Artivion, Inc. (AORT) returned -8.1% against a median move of +0.9% across the covered set. A Core-tier implant franchise lagged a set led by the therapeutics end of the sector. UNEXPLAINED

  4. 04
    MAJOR NEWS & INDUSTRY CATALYSTS

    Classification, Compliance and Surgeon Access Defined the Period's News

    Lists the period's highest-impact news events, including classification, compliance and surgeon-access developments, each linked to source.

    Classification, compliance and surgeon access were the three threads that ran through the period's news, led by MiMedx's federal court ruling vacating FDA's determination on AXIOFILL and Surrozen's IND submission for SZN-8141. Integra LifeSciences' surgeon-led programming also featured among the period's catalysts. Every 'why it matters' line here is a NeuraCap read tied to a specific filing or article, sourced in a fixed reliability order that starts with SEC filings. So what: the news that moved prices this period was regulatory and clinical, not corporate activity.

    Everything on this page

    MAJOR NEWS & INDUSTRY CATALYSTS Classification, Compliance and Surgeon Access Defined the Period's News The two-week period's highest-impact events · titles link to the underlying filing or article · September 14–28, 2026 Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. "Why it matters" lines are NeuraCap reads; each event links to its source. Sources are admitted in a fixed reliability order (SEC filings, press releases, established outlets); video and social platforms are never used. Regenerative Medicine Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 4 Sep 23 · NEWS · GlobeNewsWire MiMedx wins federal court ruling vacating FDA classification determinations on AXIOFILL The ruling goes to whether AXIOFILL is minimally manipulated or should sit as a licensed biological product. That line sets the effective life and defensibility of a franchise in this sector. Classification outcomes can reset a market faster than a product launch does. Sep 23 · NEWS · PRNewsWire LeMaitre Vascular faces class action investigation after reported exposure of customer data The probe announced by the law firm touches compliance and data handling rather than product performance. Diligence in this sector already concentrates on compliance history, and LeMaitre Vascular, Inc. Compliance exposure is weighed alongside clinical and reimbursement position in this sector. Sep 25 · NEWS · GlobeNewsWire Integra LifeSciences brings surgeon-led liver surgery education to ACS Clinical Congress 2026 Integra LifeSciences Holdings Corporation (IART) is putting surgeon-led programming behind a long-running instrumentation line. Channel ownership and surgeon access still separate platforms from single-product sellers.

  5. 05
    M&A & STRATEGIC ACTIVITY

    The Transaction Record Holds While Regulatory Outcomes Do the Work

    Reviews the trailing transaction record, noting no new deals were recorded in the current two-week window.

    No new Regenerative Medicine transactions printed in this window, so the reference set holds at 23 precedent deals, with NeuraCap's valuation lens for the sector at a median of 10.0x. We treat this as a stable baseline rather than a stale one — deal multiples are LTM at announcement where disclosed, and no prior transaction is re-presented as new. So what: acquirers get a regulatory data point this period, not a new price point, and the 10.0x lens remains the reference for underwriting the next deal.

    Everything on this page

    M&A & STRATEGIC ACTIVITY The Transaction Record Holds While Regulatory Outcomes Do the Work September 14–28, 2026 · precedent transactions: 23 recorded deals Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Deal multiples are LTM at announcement where disclosed; "why the deal happened" is a NeuraCap read of the recorded evidence. No old transactions are re-presented as news. Regenerative Medicine Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 5 No Material Transactions Announced No material sector transactions were announced during the period. The trailing record still carries 23 precedent transactions, and NeuraCap's valuation lens for the sector sits at a median of 10.0x. A quiet two-week period is information: buyer appetite, financing conditions and seller expectations all read through a period with no new deals. The precedent transactions alongside still frame what buyers have paid. 23 Recorded precedent transactions the reference set buyers and sellers price against

  6. 06
    WHAT IT MEANS

    What the Period Changes for Operators, Buyers and Advisors

    Translates the period's regulatory and market findings into implications for operators, acquirers and advisors.

    For operators, the takeaway is that channel and payment-route execution carried the set higher even without deal activity, evidenced by the +0.9% median move across five of seven rising names. For acquirers, the reference set gains a regulatory data point rather than a new price point, since the trailing record still carries 23 precedent deals against the 10.0x lens. For advisors, the evidence to lead with is the MiMedx classification ruling, Surrozen's IND submission, and Integra LifeSciences' surgeon-led programming. So what: this period argues for leading conversations with regulatory pathway, not transaction comparables.

    Everything on this page

    WHAT IT MEANS What the Period Changes for Operators, Buyers and Advisors The two-week period translated for the people who act on it · NeuraCap view · observations, not recommendations Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. This page is analytical interpretation drawn from the two-week period's recorded evidence. It is not investment advice. Regenerative Medicine Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 6 Sector study 2026-09-28 EV / EBITDA (CY2027E) median 10.0x 8 companies in the study 3 valuation tiers Standing thesis: Regenerative Medicine Splits Across Implants, Instrumentation, Therapeutics and Adjacent Models FOR OWNERS & OPERATORS Payment Route and Channel Productivity Carried the Set Companies in the space traded higher over the two-week period, with 5 of 7 covered names rising and a median move of +0.9%. FOR ACQUIRERS The Reference Set Gains a Regulatory Data Point, Not a New Price Point No transactions printed in the window, so the reference set is unchanged and the trailing record still carries 23 precedent transactions against a 10.0x median lens. The MiMedx Group, Inc. FOR ADVISORS Lead with Classification and Channel The period's theme was regulatory pathway. The evidence to lead with is the MiMedx ruling on minimal manipulation, the Surrozen, Inc. (SRZN) Investigational New Drug submission, and Integra LifeSciences Holdings Corporation (IART) surgeon-led programming.

  7. 07
    SOURCES & METHODOLOGY

    Sources, Methodology and Important Notice

    Explains the sources, methodology and important notices behind the update's figures and driver attributions.

    Every figure in this update ties back to a recorded filing, price series or transaction record, and every driver read is clearly marked as a NeuraCap interpretation rather than an asserted cause. We rely on SEC filings and established outlets first, and we never draw on video or social platforms. This discipline is what lets us stand behind the numbers on the prior six pages. So what: when a client asks where a figure came from, this page has the answer.

    Everything on this page

    SOURCES & METHODOLOGY Sources, Methodology and Important Notice How this bi-weekly update is built and what each kind of statement rests on · September 14–28, 2026 · market data through 2026-09-28 Every figure in this update links to the record it was taken from; the publishers and filings drawn on for the period are listed above. Regenerative Medicine Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice 7 OBSERVED DATA Bi-Weekly stock moves are computed close-to-close over the stated window from the platform’s price series. Deal records, values and multiples come from the platform’s transaction record (SEC 8-K extractions) exactly as recorded; each figure links to its citation. Treasury rates come from the platform’s Treasury series and are shown only when the 10-year moved at least ten basis points over the window (it did not in this window, so no rate figures appear). UNIVERSE QUALITY The update universe is the platform’s approved company set for this sector, subject to a $100M market-cap floor so small, loosely related names cannot dominate the statistics. 1 name below the floor was excluded from movers and statistics for this window. EVENTS & NEWS Company events are in-window 8-K filings; news items are publisher-sourced headlines fetched for the window (and any externally supplied items, marked as such). Operational and strategic developments (deals, partnerships, launches, expansion, guidance, leadership, regulatory outcomes) are shown first; capital-return mechanics and conference appearances are limited to one each. Every event links to its source. The deck never asserts an event that has no linked record. SOURCE HIERARCHY News is admitted in a fixed order of reliability: SEC filings first, then company press releases and investor-relations communications, then transaction documents, then established outlets (Reuters, CNBC, The Wall Street Journal, Barron’s and peers). Video and social platforms — including YouTube — are never used as sources. DRIVER ATTRIBUTION A stock move is linked to an event only when the event falls inside the window, and only in calibrated language ("the move appears to reflect…", "shares moved following…"). Where no driver is recorded, the page says so and compares the move to the sector median instead. ANALYTICAL INTERPRETATION "Why it matters", "why the deal happened" and the what-it-means page are NeuraCap analytical views drawn from the recorded evidence, and are labeled as such. INHERITED CONTEXT The standing sector view (thesis, valuation lens, sector median and tiering) is inherited from the NeuraCap sector study run_20260929T183546Z_562_prod (market data as of 2026-09-28) — distilled, never re-derived. That report’s own sources page governs its content; this update reads the period against it. IMPORTANT NOTICE This report is informational only. It is not investment advice, not a recommendation to buy or sell any security, and not an offer of any kind. Readers should perform their own diligence before acting on anything described here. Linked sources this two-week period: globenewswire.com · prnewswire.com

Sources and methodology

This update covers Regenerative Medicine over the 14-day window September 14–28, 2026; market data runs through September 28, 2026. The universe is the 7 listed companies whose core business is Regenerative Medicine under NeuraCap's industry classification, subject to a $100M market-capitalisation floor so that very small, loosely related names cannot dominate the movers and statistics. Companies covered: Artivion, Inc. (AORT), Integra LifeSciences Holdings Corporation (IART), LeMaitre Vascular, Inc. (LMAT), MiMedx Group, Inc. (MDXG), Organogenesis Holdings Inc. (ORGO), Sanara MedTech Inc. (SMTI), Surrozen, Inc. (SRZN). 1 name below the floor was excluded from the statistics: SNWV.

Window and company universe

This update covers Regenerative Medicine over the 14-day window September 14–28, 2026; market data runs through September 28, 2026. The universe is the 7 listed companies whose core business is Regenerative Medicine under NeuraCap's industry classification, subject to a $100M market-capitalisation floor so that very small, loosely related names cannot dominate the movers and statistics. Companies covered: Artivion, Inc. (AORT), Integra LifeSciences Holdings Corporation (IART), LeMaitre Vascular, Inc. (LMAT), MiMedx Group, Inc. (MDXG), Organogenesis Holdings Inc. (ORGO), Sanara MedTech Inc. (SMTI), Surrozen, Inc. (SRZN). 1 name below the floor was excluded from the statistics: SNWV.

How the moves and statistics are computed

Each company's period move is the change in closing price from the last close before the window to the last close inside it (close-to-close). The sector median is the median of those moves across the covered names; the index return is computed the same way for the S&P 500 over the same dates. The largest single-day move inside the window is shown for each mover. Movers are the largest gainers and losers by period move; the attribution cards prefer movers whose in-window record explains the move. Movers carry the valuation tier assigned in the standing sector study (the latest NeuraCap sector outlook) where that study rated them.

Events, news and how a move is attributed

Company events are the 8-K filings made inside the window; news items are publisher-sourced headlines for the window, admitted in a fixed order of reliability: SEC filings first, then company press releases and investor-relations communications, then established outlets (Reuters, CNBC, The Wall Street Journal, Barron's and peers). Video and social platforms are never used. A move is linked to an event only when the event falls inside the window and only in calibrated language; where nothing in the record explains a move, the update says so rather than speculating. Every event links to its source.

Transactions in the window and the trailing record

Transactions are taken from SEC filings by announcement date; 0 were announced inside the window. The trailing record of 23 recorded transactions provides the reference multiples (EV over last-twelve-month revenue or EBITDA at announcement, as disclosed). A value whose own citation describes something other than the price paid is not shown as the deal value; transactions where the acquirer and the target are the same entity are treated as reorganisations and excluded.

Sources

Prices and index levels are market data through September 28, 2026; filings are the companies' SEC filings on EDGAR; press releases are the companies' own; other news items are from the established outlets named on each card; Treasury yields are published by the U.S. Department of the Treasury. Every figure and every event in the update links to its record.

Interpretation and important notice

'Why it matters', 'why the deal happened' and the what-it-means page are NeuraCap analytical views drawn from the recorded evidence, labelled as such. The update is informational: it is not investment advice, not a recommendation to buy or sell any security and not an offer of any kind.

This report is published for information only. It is not a recommendation to buy or sell any security, an offer or solicitation, an appraisal or a fairness opinion, and no fiduciary relationship is created by reading it. Multiples that fail NeuraCap’s plausibility gates are excluded and never plotted. See the full methodology and the disclaimer.

Want this analysis for a company in Regenerative Medicine?

Company valuation reports run the same method against a single business — public or private.